Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.72 |
| ▸ | FNTB | P49356 | 19/20 | 0.72 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | NRAS | P01111 | 1/20 | 0.46 |
| ▸ | HRAS | P01112 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676603 | 0.94 | FNTA (0.63) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL4405095 | 0.94 | FNTA (0.63) | FNTAFNTBPGGT1BKCNH2 | |
| Hydrochloric Acid SCHEMBL8590479 | 0.93 | FNTA (0.62) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL28013379 | 0.88 | FNTA (0.55) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL31472029 | 0.84 | FNTA (1.00) | FNTAFNTBPGGT1BKCNH2NRAS | |
| SCHEMBL445625 | 0.84 | FNTA (1.00) | FNTAFNTBPGGT1BKCNH2NRAS | |
| SCHEMBL445627 | 0.84 | FNTA (1.00) | FNTAFNTBPGGT1BKCNH2NRAS | |
| SCHEMBL7855591 | 0.82 | FNTA (1.00) | FNTAFNTBPGGT1BKCNH2NRAS | |
| SCHEMBL7834328 | 0.79 | FNTA (1.00) | FNTAFNTBPGGT1BKCNH2NRAS | |
| Hydrochloric Acid SCHEMBL7849191 | 0.79 | FNTA (0.98) | FNTAFNTBPGGT1BKCNH2NRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202809-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-07-04 | — | — | US | disclosed |
| EP-2797875-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | Pharmacyclics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| EP-1556052-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1465896-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005118584-A2 | SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1515949-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1556052-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1515949-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040220201-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1465896-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004037171-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003106417-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003050122-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885PGGT1B 2532/4885 |
| US-20040220201-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | FNTA 2966/4885FNTB 3554/4885PGGT1B 4287/4885 |
| US-20190202809-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.